RxDoctor Payments Data

Johanna Green-Jacob

Family · Chula Vista, CANPI 1609863968

Payments from drug & device makers

$4,146in general payments, 2019–2025

Across 163 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$715
  • Novo Nordisk$662
  • AstraZeneca$386
  • GSK$369
  • Boehringer Ingelheim$342
  • Exact Sciences$197
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,146 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide58$79,209
OzempicSemaglutide73$74,137
Diclofenac Sodium56$37,671
JardianceEmpagliflozin37$33,082
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$20,197
EliquisApixaban16$17,495
FarxigaDapagliflozin Propanediol12$13,320
LinzessLinaclotide15$12,715
XareltoRivaroxaban11$9,054
Aripiprazole12$6,257
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,025
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,125
Atorvastatin Calcium258$3,985
Albuterol Sulfate HfaAlbuterol Sulfate117$3,141
Losartan Potassium176$2,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$715$79,20958 claims
Novo NordiskOzempic$662$74,13773 claims
Boehringer IngelheimJardiance$342$33,08237 claims
GSKTrelegy Ellipta$369$20,19721 claims
PfizerEliquis$54$17,49516 claims
AstraZenecaFarxiga$386$13,32012 claims
AbbVieLinzess$29$12,71515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →